-
2022 Medicine Summary: A New Beginning After Winter
Time of Update: 2023-02-03
In addition to the epidemic, the suppression of profit margins brought about by the two major price limit policies of volume procurement and medical insurance negotiation, and the influence of international macro environmental factors such as global decoupling and US dollar interest rate hikes this year, the prosperity of the pharmaceutical industry in the capital market has been declining all the way - the proportion of public funds in pharmaceutical stocks is close to a record low in ten years.
-
The battle for new crown oral drugs, attack on RdRp inhibitors
Time of Update: 2023-02-03
On December 26, 2021, the New England Journal of Medicine published clinical data showing that remdesivir reduced the risk of hospitalization or death by 87% compared with placebo in symptomatic and unhospitalized COVID patients at high risk of disease progression.
-
The party responded to sending a circle of friends to let montmorillonite go out of stock: a record has been made at the police station; Beijing currently admits 3% to 4% of infected people with severe disease
Time of Update: 2023-02-03
Daily medical appointmentsDaily medical appointments1 The party responded to sending a circle of friends to let the montmorillonite go out of stock: a record has been made at the police station1 The p
-
These "anti-new crown drugs" may be approved in China in the first half of this year! What are the advantages?
Time of Update: 2023-02-03
LeadLeadIn a previous article, we took stock of the anti-coronavirus drugs that are currently on the market. In this article, we will take stock of the anti-coronavirus drugs that are expected to be o
-
Yiming Biotech announced the completion of Series B expansion financing, raising a total of $131 million in Series B financing
Time of Update: 2023-02-03
Dr. Xiaoling LiaoDr. Xiaoling LiaoFounder, CEO and Chairman of Yiming BiotechnologyFounder, CEO and Chairman of Yiming Biotechnology"In the past year, Eming Biologics has achieved amazing growth and development, including two myeloid cell immune checkpoint inhibitor programs in China and the United States for the treatment of multiple cancers with urgent clinical needs.
-
11 clinical therapies to look forward to in the first quarter of 2023
Time of Update: 2023-02-03
An important event expected to receive clinical trial results or achieve regulatory progress in the first quarter of this year, including 11 innovative therapies across different fields KarXT（Karuna Therapeutics） KarXT（Karuna Therapeutics）KarXT is developed by Karuna Therapeutics develops innovative drugs for the treatment of schizophrenia in adults.
-
For $1.235 billion, PeptiDream partnered with Eli Lilly to develop PDC drugs
Time of Update: 2023-02-03
PeptiDream's R&D pipeline Original English text: _mstmutation="1" _msthash="220728" _msttexthash="2926391"> December 26 Japanese biotech company PeptiDream announced that it has entered into a joint research and licensing agreement with Eli Lilly for the creation and development of innovative peptide drug conjugates (PDCs).
-
The peak of infection may be coming, in addition to vaccines, what is the progress of new crown treatment drugs?
Time of Update: 2023-02-03
clinical trialOn December 18, Simcere Pharmaceutical announced that its anti-new coronavirus drug Xiannuoxin ™ co-developed with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Wuhan Institute of Virology has completed the enrollment of all 1208 patients in a randomized, double-blind, placebo-controlled phase II.
-
New crown "special medicine" sentient beings: some are waiting for approval, some have been sold out.....
Time of Update: 2023-02-03
According to the approval information of the State Food and Drug Administration for the import registration of Paxlovid, this product is an oral small molecule new coronavirus treatment drug, which is used to treat adult patients with mild to moderate novel coronavirus pneumonia (COVID-19) with factors at risk of progression to severe disease, such as patients with advanced age, chronic kidney disease, diabetes, cardiovascular disease, chronic lung disease and other high-risk factors for severe disease.
-
The national talk is over! Pfizer Paxlovid did not talk about success, and azvudine and lung cleansing detoxification granules entered medical insurance
Time of Update: 2023-02-03
01 Paxlovid was successfully reimbursed until March 31 due to high quotations01 Paxlovid was successfully reimbursed until March 31 due to high quotationsThe negotiation of the 2022 national medical i
-
I found these things worth paying attention to in 2023 on Nature...
Time of Update: 2023-02-03
Resources: Resources: BioNTech official website BioNTech official website Moderna's official website Moderna's official website Vertex official website Vertex official website Eisai's official website Eisai's official website Other publicly available information Other publicly available information Nature expects the World Health Organization (WTO) to publish a revised list of priority pathogens.
-
The development status and prospect of AI+ medical device industry
Time of Update: 2023-02-03
Figure: Approval of NMPA in three types of artificial intelligence medical imaging certificates from 2020 to 2022 Source: Flint Creation, compiled based on publicly available data Figure: Approval of AI medical imaging three types of devices from 2020 to 2022 Source: Flint Creation is based on public informationAI Robot China's surgical robot industry has developed rapidly, and the average annual compound growth rate of market size in the past 5 years has exceeded 30%.
-
Metagenomi completed $275 million Series B funding to advance its gene editing pipeline
Time of Update: 2023-02-03
Thomas said: Original link: _mstmutation="1" _msthash="220731" _msttexthash="6493708"> On Jan. 5, Metagenomi, a gene drug company with a range of wholly-owned next-generation gene-editing systems, announced the closure of a $100 million Series B+ funding round by Novo Holdings, Catalio Capital Management and SymBiosis, co-led, with new and existing investor participation, including Leaps by Bayer and Moderna, as well as initial Series B investors PFM Health Sciences and Farallon Capital Management and a leading global investment firm.
-
Spring River Plumbing CXO Prophet
Time of Update: 2023-02-03
WuXi AppTec's DDSU (Domestic New Drug R&D) business is an important window to observe the trend of domestic innovative drugs, and revenue in the first three quarters of this year fell by 27.
-
Studies have shown that drugmakers profit greatly from secondary patents for inhalation devices
Time of Update: 2023-02-03
This article from JAMA indicates that from 2000 to 2021 years, drugmakers listed "much more" secondary patents than primary patents and earned "much more revenue" after the active ingredient expired.
-
Where is the innovation and transformation path for local pharmaceutical companies?
Time of Update: 2023-02-03
From the sales of generic drugs in the past to the record high number of clinical applications for new drugs in recent years, "innovation transformation" has become an important proposition for the sustainable development of local pharmaceutical companies.
-
Overview of China's medical science and technology policies in 2022: comprehensive efforts to transform scientific and technological achievements
Time of Update: 2023-02-03
In 2022, the situation at home and abroad will be complex and changeable, and the global economic development and scientific and technological exchanges will face major setbacks and challenges. Innova
-
Widest coverage! The marketing application of Pfizer pentavalent meningococcal vaccine was accepted by the FDA
Time of Update: 2023-02-03
Together, the five serogroups (A, B, C, W, Y) account for 96% of all invasive meningococcal disease cases globally Information Reference: Information Reference: Annaliesa, senior vice president and chief scientific officer of Pfizer vaccine research and development "The FDA's acceptance of our pentavalent meningococcal vaccine candidate is an important step in helping individuals and communities prevent the most common types of meningococcal disease," Anderson said.
-
Domestic oncology NGS enterprises go overseas to find technological and commercial leaps
Time of Update: 2023-02-03
On January 3, Burnstone Medical announced that its pan-cancer early screening products were recognized by the FDA as breakthrough therapies.
On January 3, Burnstone Medical announced that its pan-cancer early screening products were recognized by the FDA as breakthrough therapies.
-
R&D's 2022: Mo Dao's floating clouds end the day, and the harsh winter has bloomed spring buds
Time of Update: 2023-02-03
Words written in front2022 is extraordinary. For Chinese, 2022 was an exceptionally difficult year, with the global economy continuing to decline under factors such as the coronavirus pandemic and geo
